Evidence map›Paper›PMID 36739399›Full record

ArticleBMC oral health2023

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.

Rodolfo Mauceri, Martina Coppini, Massimo Attanasio, Alberto Bedogni, Giordana Bettini, Vittorio Fusco, Amerigo Giudice, Filippo Graziani, Antonia Marcianò, Marco Nisi and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC oral health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Prevalence and risk factors of MRONJ in breast cancer patients with CTIBL.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  9. Review
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Letter to Editor regarding "Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rodolfo MauceriDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Via L. Giuffrè 5, 90127, Palermo, PA, Italy. rodolfo.mauceri@unipa.it.
Martina CoppiniDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Via L. Giuffrè 5, 90127, Palermo, PA, Italy.
Massimo AttanasioDepartment of Economics, Business and Statistics, University of Palermo, 90128, Palermo, Italy.
Alberto BedogniRegional Center for Prevention, Diagnosis, and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padova, 35128, Padova, Italy.
Giordana BettiniRegional Center for Prevention, Diagnosis, and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padova, 35128, Padova, Italy.
Vittorio FuscoOncology Unit, Azienda Ospedaliera Di Alessandria SS. Antonio e Biagio e Cesare Arrigo, 15121, Alessandria, Italy.
Amerigo GiudiceSchool of Dentistry, Department of Health Sciences, Unit of Oral and Maxillofacial Surgery, "Magna Grecia" University of Catanzaro, 88100, Catanzaro, Italy.
Filippo GrazianiDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56126, Pisa, Italy.
Antonia MarcianòDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98124, Messina, Italy.
Marco NisiDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56126, Pisa, Italy.
Gaetano IsolaDepartment of General Surgery and Medical Surgery Specialties, School of Dentistry, University of Catania, 95123, Catania, Italy.
Rosalia Maria LeonardiDepartment of General Surgery and Medical Surgery Specialties, School of Dentistry, University of Catania, 95123, Catania, Italy.
Giacomo OteriDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98124, Messina, Italy.
Corrado ToroMaxillofacial Surgery Unit, Clinica del Mediterraneo di Ragusa, 97100, Ragusa, Italy.
Giuseppina CampisiDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Via L. Giuffrè 5, 90127, Palermo, PA, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRONJ.

methodsThis multicentre hospital-based retrospective study included consecutive non-metastatic BC patients affected by MRONJ related to exposure to low-dose BMAs for CTIBL prevention. Patients' data were retrospectively collected from the clinical charts of seven recruiting Italian centres.

resultsMRONJ lesions were found in fifteen females (mean age 67.5 years), mainly in the mandible (73.3%). The mean duration of BMAs therapy at MRONJ presentation was 34.9 months. The more frequent BMAs was denosumab (53.3%). Ten patients (66.7%) showed the following local risk factors associated to MRONJ development: periodontal disease (PD) in three cases (20%) and the remaining six (40%) have undergone PD-related tooth extractions. One patient presented an implant presence-triggered MRONJ (6.7%). In five patients (33.3%) no local risk factors were observed.

conclusionsThis is the first case series that investigated BC patients under BMAs for CTIBL prevention suffering from MRONJ. These patients seem to have similar probabilities of developing MRONJ as osteo-metabolic ones. Breast cancer patients under BMAs for CTIBL prevention need a regular prevention program for MRONJ, since they may develop bone metastases and be treated with higher doses of BMAs, potentially leading to a high-risk of MRONJ.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsBreast NeoplasmsAgedDiphosphonatesFemaleHumansRetrospective StudiesBone Density Conservation AgentsDiphosphonatesBone modifying agentsBreast cancerCancer treatment-induced bone lossCTIBLMRONJONJOsteonecrosis of the jaw

Identifiers

PMID36739399
PMCPMC9899375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.